KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bionano Genomics (BNGO) Operating Margin (2017 - 2025)

Bionano Genomics' Operating Margin history spans 7 years, with the latest figure at 115.9% for Q3 2025.

  • For Q3 2025, Operating Margin rose 60703.0% year-over-year to 115.9%; the TTM value through Sep 2025 reached 127.93%, up 22306.0%, while the annual FY2024 figure was 337.87%, 25811.0% up from the prior year.
  • Operating Margin for Q3 2025 was 115.9% at Bionano Genomics, roughly flat from 115.8% in the prior quarter.
  • Across five years, Operating Margin topped out at 115.8% in Q2 2025 and bottomed at 1214.95% in Q3 2023.
  • The 5-year median for Operating Margin is 444.21% (2021), against an average of 410.85%.
  • The largest annual shift saw Operating Margin plummeted -76973bps in 2023 before it soared 60703bps in 2025.
  • A 5-year view of Operating Margin shows it stood at 456.73% in 2021, then dropped by 0bps to 456.81% in 2022, then soared by 49bps to 232.75% in 2023, then surged by 37bps to 146.28% in 2024, then increased by 21bps to 115.9% in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Operating Margin are 115.9% (Q3 2025), 115.8% (Q2 2025), and 131.1% (Q1 2025).